Scan to Download ios&Android APP

Trade SurModics - SRDX CFD

-
0%

SurModics live chart

Still looking for a broker you can trust?
Capital.com Group
400,000+

Traders

90,000+

Active clients monthly

$65,000,000+

Monthly investing volume

$29,000,000+

Withdrawn each month

  • Summary
  • Historical Data
Trading Conditions
Long position overnight fee
-0.0225%
Short position overnight fee
-0.0219%
Overnight fee time
21:00 (UTC)
Min traded quantity
1
Currency
USD
Margin
20%
Stock exchange
United States of America
Commission on trade
0%
  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low

Content 2
Content 2

Key Stats

Prev. Close* N/A
Open* N/A
Day's Range* N/A
1-Year Change* N/A
Volume N/A
Average Vol. (3m) 0.81143
52 wk Range N/A
Market Cap 554.004
P/E Ratio N/A
Shares Outstanding 13.99M
Revenue 96.953
EPS -0.75443
Dividend (Yield %) N/A
Beta 1.06688
Next Earnings Date Aug 2, 2022

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

SurModics Company profile

About SurModics, Inc.

Surmodics, Inc. is a provider of surface modification technologies for intravascular medical devices and chemical components for in vitro diagnostic (IVD) immunoassay tests and microarrays. The Company operates through two segments: Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment consists of surface modification coating technologies to improve access, deliverability and predictable deployment of medical devices, as well as drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device, with end markets that includes coronary, peripheral, neurovascular and structural heart, among others. The IVD segment designs, develops and manufactures component products and technologies for diagnostic immunoassay, as well as molecular tests and biomedical research applications, with products that include protein stabilization reagents, substrates, surface coatings and antigens.

Financial summary

BRIEF: For the three months ended 31 December 2021, SurModics, Inc. revenues increased 3% to $23M. Net loss increased from $274K to $2.8M. Revenues reflect Medical Device segment increase of 4% to $16.9M. Higher net loss reflects Medical Device segment loss increase from $593K to $3.8M, Corporate segment loss increase of 11% to $2.8M, In Vitro Diagnostics segment income decrease of 2% to $3.2M.

Equity composition

Common Stock $.05 Par, 02/11, 45M auth., 17,488,245 issd. Insiders control 4.93%. IPO: 3/98, 2M shares @ $7.50 by John G. Kinnard & Co. 12/00, 2-for-1 stock split. All Preferred Stock converted to Common at IPO. FY'03 financials are and FY'04 Q's are being CLA. 3/04 and 3/03 Q's = 6 months.

Industry: Medical Equipment, Supplies & Distribution (NEC)

9924 W 74th St
EDEN PRAIRIE
MINNESOTA 55344
US

People Also Watch

US Natural Gas Spot

6.24 Price
-0.050% 1D Chg, %
Long position overnight fee -0.0345%
Short position overnight fee 0.0165%
Overnight fee time 21:00 (UTC)
Spread 0.020

Still looking for a broker you can trust?

Join the 400.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading